Rangering i aksjer
#39494
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing... Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
Aksjekurs
$0.1174299
Sist synkronisert: 2026-08-13
Handel Vaxil Bio Ltd. (VXL)
Pris VXL pris med markedsverdi på B
Markedsverdi av Vaxil Bio Ltd.(VXL)
Markedsverdi: $467.84K
Per August 2026 har Vaxil Bio Ltd. en markedsverdi på $467.84K. Dette gjør Vaxil Bio Ltd. til det 39494th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Vaxil Bio Ltd. fra 2010 til 2026
VXL sammenlignet med topp 5 mest populære stocks
| Pris på VXL |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.453T
|
+1,165,618,084.47%
|
|
|
|
|
$4.488T
|
+959,362,455.72%
|
|
|
|
|
$4.161T
|
+889,434,962.26%
|
|
|
|
|
$3.698T
|
+790,491,449.85%
|
|
|
|
|
$2.835T
|
+606,071,786.14%
|
